Role of Genetic Variations in CDK2, CCNE1 and p27KIP1 in Prostate Cancer

Background/Aim: Our aim was to investigate possible influences of genetic variants in genes involved in the G(1)/S transition [cyclin-dependent kinase-2 (CDK2), cyclin E1 (CCNE1) and cyclin-dependent kinase inhibitor 1B (p27(KIP1))] on the expression/activity of their corresponding proteins and to assess the functional impact of these variants on the risk of prostate cancer. Materials and Methods: We genotyped 530 cases and 562 healthy controls for two relevant single nucleotide polymorphisms (CDK2 rs2069408 and CCNE1 rs997669) by TaqMan genotyping assay. p27(KIP1) rs2066827 polymorphisms were studied by polymerase chain reaction-restriction fragment length polymorphism assay. In addition, the expression of CDK2, CCNE1 and p27(KIP1) was evaluated by quantitative real-time-polymerase chain reaction and western blotting in 44 prostate cancer tissues and 31 benign prostatic hyperplasia tissues. Results: No association was found between CDK2 rs2069408, CCNE1 rs997669 or p27(KIP1) rs2066827 polymorphisms and an increased risk of prostate cancer development. Higher CDK2 expression was more prevalent in those with rs2069408 GG genotype than in AA carriers (p>0.05). We also noted reduced p27(KIP1) protein expression in those with the p27(KIP1) G109 allele. No difference was observed for CCNE1 expression in relation to the risky genotype (CC). A significant association was detected between CCNE1 mRNA overexpression and development of higher-grade carcinomas (Gleason score >7, p<0.05). Conclusion: Polymorphisms CDK2 rs2069408, CCNE1 rs997669 and p27(KIP1) rs2066827 have no significant impact on prostate cancer risk nor on the gene and protein expression of CDK2, CCNE1 and p27(KIP1), although high CCNE1 expression was significantly associated with a higher tumour grade in patients with prostate cancer.

Automated summary

Genetic variants in genes involved in the G1/S transition (CDK2, CCNE1, and p27(KIP1)) did not have a significant impact on prostate cancer risk or the expression/activity of their corresponding proteins. However, high CCNE1 expression was significantly associated with a higher tumor grade in patients with prostate cancer.